"Couple's Immunotherapy": Is CXCL13 at the Heart of the Prescription?
Cancer Immunol Res
; 12(8): 952-953, 2024 Aug 01.
Article
em En
| MEDLINE
| ID: mdl-38967231
ABSTRACT
Sex differences in cancer survivorship and response to immunotherapy have been observed, with males generally displaying better outcomes to immune checkpoint blockade compared with females. In this article, by interrogating public lung cancer sequencing datasets, Brennan and colleagues uncover a chemokine axis that may contribute to disparate immunotherapy outcomes between the sexes. See related article by Brennan et al., p. 956 (3).
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Quimiocina CXCL13
/
Imunoterapia
Idioma:
En
Ano de publicação:
2024
Tipo de documento:
Article